Medical Therapy. Efficacy or Lack of Efficacy

Juvenile Systemic Sclerosis Presenting With Severe Pulmonary Vascular Disease: ECMO Stabilization During Aggressive Therapy Resulting in a Favorable Outcome

Stephanie M. Tsoi, Shannon Cheung, Roberto Alejandro Valdovinos, Elena Amin, Hythem Nawaytou, Elizabeth Colglazier, Claire Parker, April Edwell, Susan Kim, Jeffrey R. FinemanUniversity of California San Francisco. Pulmonary CirculationPulm Circ 2025; 15: DOI: 10.1002/pul2.70106 AbstractJuvenile systemic sclerosis (jSSc) associated pulmonary hypertension (PH) is rare, but, the leading cause of morbidity and mortality in jSSc. This is […]

Juvenile Systemic Sclerosis Presenting With Severe Pulmonary Vascular Disease: ECMO Stabilization During Aggressive Therapy Resulting in a Favorable Outcome Read More »

Pulmonary artery-targeted low-dose metformin-loaded nanocapsules safely improve pulmonary arterial hypertension in rats

Ayako Chida-Nagai, Naoki Masaki, Hiroki Sato, Tatsuya Kato, Emi Takakuwa, Yoshihiro Matsuno, Atsushi Manabe, Atsuhito TakedaHokkaido University Hospital. Tokyo Women’s Medical University. Tohoku University Graduate School of Medicine. Oita University and Oita University Hospital.Japan Frontiers in PediatricsFront Pediatr 2025; 16: DOI: 10.3389/fphar.2025.1577570 AbstractIntroduction: Pulmonary arterial hypertension (PAH) remains a challenge to tackle despite various available medications. Metformin,

Pulmonary artery-targeted low-dose metformin-loaded nanocapsules safely improve pulmonary arterial hypertension in rats Read More »

MHCIIhiLYVE1loCCR2hi Interstitial Macrophages Promote Medial Fibrosis in Pulmonary Arterioles and Contribute to Pulmonary Hypertension

Fan Qiu, Hao-Ran Miao, Hong-Liang Hui, Lin-Jie Qiu, Yi Chen, Min Luo, Jian-Chao Zhang, Yan-Gui Lin, Dan Li, Sang-Bing Ong, Xue-Fei Hu, Bo Jiang, Yi-Qian ZhangEighth Affiliated Hospital of Sun Yat-sen University. Chinese University of Hong Kong. Hong Kong Children’s Hospital. China and Hong Kong Circulation ResearchCirc Res 2025; DOI: 10.1161/CIRCRESAHA.125.326173 AbstractBackground: Pulmonary hypertension (PH) is a

MHCIIhiLYVE1loCCR2hi Interstitial Macrophages Promote Medial Fibrosis in Pulmonary Arterioles and Contribute to Pulmonary Hypertension Read More »

Cyclopamine Attenuates Pulmonary Arterial Hypertension Development: Implications of Hedgehog Signaling Involvement for the Pathophysiology

Makito Sakurai, Susumu Hosakawa, Yohei Yamaguchi, Susumu Kirimura, Kensuke Ihara, Kenichi Ohashi, Tetsushi Furukawa, Tetsuo Sasano, Kenichi Kashimada, Taku IshiiInstitute of Science Tokyo. Japanese Red Cross Musashino Hospital.  National Center for Child Health and Development. Japan Federation of American Societies for Experimental Biology JournalFASEB J 2025; 39: DOI: 10.1096/fj.202403350R AbstractPulmonary arterial hypertension (PAH) is one of

Cyclopamine Attenuates Pulmonary Arterial Hypertension Development: Implications of Hedgehog Signaling Involvement for the Pathophysiology Read More »

Role of phosphodiesterase-3 inhibitor in cardiorespiratory fitness and functional class of patients with pulmonary hypertension: A randomized, double-blind, placebo-controlled trial

Sefri N. Sofia, Udin Bahrudin, Ilham Uddin, Muhammad A. Sobirin, Erna Setiawati, Galuh Hardaningsih, Kevin C. Tjandra, Edward K. S. LimijadiUniversitas Diponegoro. Dr. Kariadi Hospital. Indonesia Narra JNarra J 2025; 5: DOI: 10.52225/narra.v5i1.1301 AbstractMany patients with acyanotic shunt congenital heart disease (CHD) are diagnosed only in adulthood, by which time pulmonary hypertension (PH) has developed, impairing

Role of phosphodiesterase-3 inhibitor in cardiorespiratory fitness and functional class of patients with pulmonary hypertension: A randomized, double-blind, placebo-controlled trial Read More »

Inhibiting Serotonin Synthesis for the Treatment of Pulmonary Arterial Hypertension

Georg Hansmann, Michael BaderFriedrich-Alexander-University Erlangen-Nürnberg. Trypto Therapeutics. Charité-Universitätsmedizin. University of LübeckGermany Pulmonary CirculationPulm Circ 2025; 15: DOI: 10.1002/pul2.70100 AbstractAbstract Not Available CategoryMedical Therapy. Efficacy or Lack of EfficacyMedical Therapy. Adverse Effects or Lack of Adverse Effects Age Focus: No Age-Related Focus Fresh or Filed Publication: Fresh (PHresh). Less than 1-2 years since publication Article Access Free

Inhibiting Serotonin Synthesis for the Treatment of Pulmonary Arterial Hypertension Read More »

Comparative study between nebulized and intravenous magnesium sulfate for treatment of persistent pulmonary hypertension in neonates

Nashwa Farouk Mohamed, Osama Abu El Fetouch Zaki El Feky, Heba Morsy Saad El Din El Ganady, Walid Abd Elatif Abd El HalimBenha University.Egypt Journal of Neonatal-Perinatal MedicineJ Neonatal Perinatal Med 2025; 18: 246-254DOI: 10.1177/19345798251325510 AbstractBackground: Persistent pulmonary hypertension of the newborn (PPHN) is a life-threatening condition resulting from elevated pulmonary vascular resistance, causing severe hypoxemia.

Comparative study between nebulized and intravenous magnesium sulfate for treatment of persistent pulmonary hypertension in neonates Read More »

Persistent pulmonary hypertension of the newborn infant (PPHN) due to premature closure of the ductus arteriosus (DA)

Ayevbekpen Grace Okoye, Adrita Khawash, Mahesh Nanjundappa, Matthew Jones, Anne GreenoughKings College Hospital NHS Foundation Trust. Evelina Children’s Hospital and Guys and St Thomas Hospital. United Kingdom Case Reports in Perinatal MedicineCase Rep Perinat Med 2025; 13: DOI: 10.1515/crpm-2024-0001 AbstractObjectives: To describe the course of an infant with persistent pulmonary hypertension of the newborn (PPHN) secondary to

Persistent pulmonary hypertension of the newborn infant (PPHN) due to premature closure of the ductus arteriosus (DA) Read More »

Mechanism and Treatment of Right Ventricular Failure Due to Pulmonary Hypertension in Children

Bibhuti B. DasUniversity of Mississippi Medical Center.United States ChildrenChildren 2025; 12: DOI: 10.3390/children12040476 AbstractPulmonary hypertension (PH) is a progressive disorder characterized by obstructive changes in the pulmonary vasculature, leading to increased pulmonary vascular resistance (PVR), right ventricular (RV) strain, and eventual RV failure (RVF). Despite advancements in medical therapy, PH remains associated with significant morbidity and

Mechanism and Treatment of Right Ventricular Failure Due to Pulmonary Hypertension in Children Read More »

Different Effects of Riociguat and Vericiguat on Pulmonary Vessels and Airways

Katharina Nubbemeyer, Julia Krabbe, Svenja Böll, Anna Michely, Sebastian Kalverkamp, Jan Spillner, Christian MartinRWTH Aachen University. Ruhr University Bochum. Germany BiomedicinesBiomedicines 2025; 13: DOI: 10.3390/biomedicines13040856 AbstractBackground/Objectives: Pulmonary hypertension is a progressive disease leading to right heart failure. One treatment strategy is to induce vasodilation via the nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate (NO-sGC-cGMP) signaling pathway. There

Different Effects of Riociguat and Vericiguat on Pulmonary Vessels and Airways Read More »

Scroll to Top